TL;DR — Key Takeaways
- In a practice sale, who bears the malpractice tail obligation follows the deal structure: asset sales generally leave pre-closing liabilities (and the tail problem) with the seller, while entity sales hand the buyer a corporation with its history attached.
- Tail is routinely a negotiated closing item: a closing deliverable with proof of coverage, an escrow or holdback sized to the premium, and representations about prior acts.
- Sellers usually face two layers of exposure, the individual physicians’ coverage and the entity’s, and dissolving the practice entity after closing does not make prior-acts claims disappear.
- Nose (prior acts) coverage from a successor carrier is the structural alternative to buying tail, and sophisticated deals price the two options against each other.
- The seller’s tail decision should account for California’s discovery rule, which can bring claims years after closing.
The Direct Answer
When a California medical practice sells, the malpractice tail question is decided twice: first by the form of the deal, then by the purchase agreement. An asset deal generally leaves pre-closing malpractice exposure with the selling entity and its physicians, which is why buyers demand proof that the seller bought tail. An entity deal transfers the corporation with its liabilities aboard, which is why those buyers demand it even more insistently. Either way, tail belongs on the closing checklist next to consents and payoff letters, not in the pile of things to sort out afterward.
Bay Legal, PC represents sellers and buyers of California medical practices, including the compliance and insurance allocation questions that ride along with every deal. Call (650) 668-8000 in Northern California or (213) 668-8000 in Southern California to discuss a transaction.
Why Deal Structure Sets the Default
Asset sales. The buyer purchases equipment, goodwill, records custody arrangements, and contracts it elects to assume, and it generally does not assume pre-closing malpractice liability. The claims stay where they always lived: with the selling entity and the individual clinicians who provided the care. That sounds like a buyer-side comfort, and it mostly is, but successor-liability theories exist at the margins, and no buyer wants to test them. So even in asset deals, the buyer’s counsel will insist the seller’s coverage story be airtight.
Entity (stock or membership interest) sales. The buyer acquires the professional corporation itself. Every claim that arrives tomorrow about care rendered five years ago arrives at a company the buyer now owns. Prior-acts protection is not optional in this structure; it is the deal. Buyers here typically require tail (or equivalent nose coverage) at defined limits and duration as a condition to closing, backed by indemnification.
A note specific to medicine: in California, the selling entity is typically a professional corporation whose shares must be held by licensed persons, so pure stock deals have a narrower lane in healthcare than in general M&A, and many practice transactions are structured as asset deals for exactly that reason. The tail analysis above travels with whichever form the deal takes.
The Seller’s Two Layers of Exposure
Sellers often think of tail as one purchase. It is usually two questions:
The individual physicians. Each clinician insured under the practice’s claims-made policy needs their reporting rights preserved: a tail, nose coverage with the next carrier, or a qualifying retirement waiver. A selling physician who is retiring may qualify for a free retirement tail if the carrier’s tenure and permanent-retirement conditions are met, which can meaningfully change the economics of the deal’s insurance line. Our retirement pillar covers those provisions.
The entity. The professional corporation itself is typically a named insured, and claims frequently name the entity alongside the physician. An entity-level tail, sometimes called wind-down or runoff coverage, protects the corporation (and, practically, the sale proceeds sitting behind it) through the post-closing claim window.
And dissolution is not an escape hatch. California’s survival statute keeps a dissolved corporation alive to defend claims, and post-dissolution claims can be enforced against undistributed assets, including insurance, and in defined circumstances against shareholders up to what was distributed to them. Translation for sellers: dissolving the PC without tail converts a corporate exposure into a personal one. We cover the wind-down mechanics in a companion post on dissolving a medical corporation.
How Purchase Agreements Handle Tail
Four provisions do most of the work:
A covenant and closing deliverable. The agreement obligates the seller (or allocates to the buyer, if that is the negotiated deal) to purchase tail at specified limits and duration, effective at closing, with a certificate of coverage delivered as a closing condition. Vague “seller shall maintain appropriate insurance” language is where post-closing disputes are born; the better practice names the limits, the duration, and who pays.
Escrow or holdback. Where the buyer doubts the seller will follow through, or the premium is unquoted at signing, a slice of the purchase price sits in escrow until proof of tail lands. Deal practice varies: some escrows simply secure the one-time premium; publicly filed agreements show structures reimbursing tail costs across multiple renewal periods. The size should track a real quote, not a guess, which is a reason to get the carrier’s tail quote early in the process.
Representations and warranties. The seller represents its coverage history: claims-made vs. occurrence, retroactive dates, limits, known claims and incidents, and no gaps. A missed retroactive date or an undisclosed incident discovered after closing becomes an indemnification claim, so the diligence here is not a formality.
Indemnification interplay. Robust tail at healthy limits shrinks the buyer’s real exposure to pre-closing malpractice, which in turn is an argument for smaller indemnity escrows and shorter survival periods on the insurance reps. Sellers should make that argument explicitly; the tail premium buys negotiating room elsewhere in the agreement.
The Nose Coverage Alternative
Buying tail from the seller’s outgoing carrier is not the only structure. Prior acts (nose) coverage has the successor carrier honor the original retroactive date, folding the old exposure into the new program. In a practice acquisition, that can mean the buyer’s carrier picks up the acquired clinicians’ history, or the continuing physicians carry their retro dates to the buyer’s policy.
Whether nose beats tail is a pricing and availability question for the brokers, and it is genuinely case-by-case. What belongs to the lawyers is making the purchase agreement match whichever structure is chosen: if the plan is nose coverage, the closing condition and reps need to say so, and the fallback if the successor carrier declines the retro date needs to be written down before closing, not negotiated after.
If you are structuring a sale or acquisition and the insurance allocation is still a loose end, Bay Legal, PC can help you close it. Reach us at baylegal.com/contact, or call (650) 668-8000 or (213) 668-8000.
The Buyer’s Chair, Briefly
This post is written from the seller and allocation side. Buyer-side tail diligence, what to demand, what the seller isn’t telling you, and how tail fits the broader compliance review of a healthcare acquisition, is covered in our companion series on buying California treatment businesses, including a dedicated post on tail insurance and professional liability in acquisitions. The one-sentence version for buyers: require proof of tail or nose coverage as a closing condition, verify the retroactive date yourself, and treat “we’ve never been sued” as the beginning of diligence rather than the end.
MSO Structures and Investor-Backed Deals
Where the transaction involves a management services organization, a friendly-PC structure, or private equity, tail allocation picks up a regulatory layer: who may lawfully bear clinical liability costs intersects with California’s corporate practice of medicine doctrine, and 2026 legislation tightened scrutiny of MSO arrangements and added state pre-closing notice requirements for certain healthcare transactions. Those issues get their own post in this series; for deal timing purposes, know that the notice regimes can add months, and the tail allocation in the management agreement deserves review alongside the purchase agreement rather than after it.
Timing and Process: A Seller’s Sequence
A workable order of operations, which typically runs alongside the deal itself:
- Early diligence on your own coverage. Pull the policies. Confirm claims-made vs. occurrence, retro dates, who is named, and the carrier’s tail and retirement-waiver terms before the buyer asks.
- Get the tail quote early. The premium is a real number in the deal economics, frequently a multiple of the annual premium, and it prices the escrow discussion.
- Negotiate the allocation explicitly. Who pays, at what limits, for how long, individual and entity layers both.
- Paper it as a closing condition. Certificate delivered at closing; escrow released on proof.
- Mind the election window. Tail elections after policy termination run on short carrier deadlines. Closing mechanics should never leave the tail election to the week after funding.
Every practice sale allocates the past as well as the future. Getting the tail terms right is how a seller actually walks away. Bay Legal, PC helps California practice owners structure and close these transactions. Call (650) 668-8000 (Northern California) or (213) 668-8000 (Southern California), or contact us at baylegal.com/contact.
Frequently Asked Questions
Who pays for tail coverage when a medical practice is sold?
Whoever the purchase agreement says. Sellers commonly bear it in asset deals because pre-closing liability stays with them, but the allocation is negotiable, and buyers sometimes fund it in exchange for price or indemnity concessions. The mistake is leaving it unaddressed.
Do I need tail coverage if I sell through an asset sale?
Generally yes, at both the individual and entity level, because pre-closing malpractice exposure typically remains with the selling entity and its clinicians. The buyer will usually require proof of it regardless.
What happens to malpractice liability in a stock sale of a medical practice?
The buyer acquires the entity with its liabilities, so claims about pre-closing care arrive at the company the buyer now owns. That is why entity deals treat prior-acts coverage as a closing condition backed by indemnification.
Can I just dissolve my professional corporation instead of buying tail?
Dissolution does not eliminate exposure. California law keeps a dissolved corporation available to defend claims, and post-dissolution claims can reach undistributed assets and, in defined circumstances, shareholders up to what they received. Wind-down tail exists for exactly this situation.
Is nose coverage better than tail in a practice sale?
Sometimes. Nose coverage from the successor carrier can replace a tail purchase and is occasionally cheaper, but availability is carrier-specific. Price both, and make sure the purchase agreement reflects the structure actually chosen.
